Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs YieldMax TSLA Option Income Strategy ETF (TSLY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs YieldMax TSLA Option Income Strategy ETF — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while YieldMax TSLA Option Income Strategy ETF trades at $21.9. The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, YieldMax TSLA Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| BIO | TSLY | |
|---|---|---|
Market Cap | $9.43B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $356.25 | $48.25 |
52-Week Low | $241.71 | $20.49 |
Enterprise Value | $9.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TSLY trades at $21.55, up 1.03% today, with a bearish technical signal from moving averages and mixed oscillators. The ETF maintains a high dividend yield strategy, with recent weekly distributions averaging around $0.28 per share. Support and resistance levels are tightly clustered near the current price, indicating limited near-term price movement potential.
The outlook for TSLY is cautious due to capped upside from its option income structure and dependence on Tesla's volatility. Risks include missed participation in Tesla rallies and high distribution volatility. Analyst sentiment has shifted to neutral, reflecting concerns over sustainable yield and growth constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About YieldMax TSLA Option Income Strategy ETF
TSLY is an actively managed ETF that seeks to provide high monthly income by employing a synthetic covered call strategy on Tesla, Inc. (TSLA). It does not own Tesla stock directly; instead, it uses a combination of call and put options to simulate long exposure while simultaneously selling call options to collect premiums. It is designed for income-focused investors who are willing to trade TSLA's potential upside for immediate, aggressive yield.
Read more on TSLY →
